Promising Results from Govorestat Trial for CMT-SORD Shared at PNS 2025

Applied Therapeutics has presented full 12-month clinical results from the INSPIRE Phase 2/3 trial of Govorestat in people with CMT-SORD. The encouraging findings were shared during a late-breaking session at the Peripheral Nerve Society 2025 Annual Meeting.

You can read the full press release here:
🔗 https://ir.appliedtherapeutics.com/node/10191/pdf